ShedRx vs EverSlim
Two GLP-1 desks, one scoreboard. We put ShedRx and EverSlim head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Too close to call on the Brief Score.
ShedRx and EverSlim are level at 87/100. The scores won't separate them, so the pick comes down to fit: ShedRx for readers who want an oral or sublingual option, or one of the lower tirzepatide prices on the tracker. EverSlim for readers who want budget-minded patients wanting flat-price compounded glp-1 care shipped nationwide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| ShedRx | EverSlim | |
|---|---|---|
| Brief Score | 87/100 (B+) | 87/100 (B+) |
| Semaglutide | $199/mo | $127/mo |
| Tirzepatide | $299/mo | $183/mo |
| Coverage | Not disclosed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Fallingprice falling | Newnew to the tracker, no prior reading |
ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.
EverSlim: New to the tracker on 1 August 2026. The published line reads $127/mo at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.